Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries Limited American Depositary Shares | Fremanezumab | Cluster headache | Phase 3 | Trial Discontinued | Subcutaneous | Neurology |
| Teva Pharmaceutical Industries Limited American Depositary Shares | ICS/SABA (56248) | Asthma | Phase 3 | Ongoing | Inhalation | Respiratory |
| Teva Pharmaceutical Industries Limited American Depositary Shares | AUSTEDO (deutetrabenazine) | Tourette Syndrome | Phase 2/3 | Trial Discontinued | oral | Neurology |
| Teva Pharmaceutical Industries Limited American Depositary Shares | Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD) | Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD) | Phase 2b | Data Released | Oral | Gastroenterology |
| Teva Pharmaceutical Industries Limited American Depositary Shares | Emrusolmin (TEV-56286) | Multiple System Atrophy (MSA) | Phase 2 | Ongoing | Oral | Neurology |
| Teva Pharmaceutical Industries Limited American Depositary Shares | Anti-TL1A (48574) | Ulcerative colitis / Crohn's disease | Phase 2 | Ongoing | Intravenous | Gastroenterology |
| Teva Pharmaceutical Industries Limited American Depositary Shares | TEV-53275 | Asthma | Phase 2 | Trial Completed | oral | Respiratory |
| Teva Pharmaceutical Industries Limited American Depositary Shares | TEV-48574 | Irritable Bowel Syndrome (IBS) | Phase 2 | Trial Completed | oral | Gastroenterology |
